KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Deferred Taxes (2016 - 2025)

Eli Lilly's Deferred Taxes history spans 17 years, with the latest figure at $748.1 million for Q4 2025.

  • For Q4 2025, Deferred Taxes fell 22.61% year-over-year to $748.1 million; the TTM value through Dec 2025 reached $1.7 billion, down 36.38%, while the annual FY2025 figure was $1.7 billion, 36.38% down from the prior year.
  • Deferred Taxes reached $748.1 million in Q4 2025 per LLY's latest filing, up from -$501.4 million in the prior quarter.
  • In the past five years, Deferred Taxes ranged from a high of $1.1 billion in Q3 2022 to a low of -$501.4 million in Q3 2025.
  • Average Deferred Taxes over 5 years is $485.9 million, with a median of $468.6 million recorded in 2023.
  • Peak YoY movement for Deferred Taxes: skyrocketed 4967.31% in 2023, then tumbled 216.66% in 2025.
  • A 5-year view of Deferred Taxes shows it stood at $92.5 million in 2021, then crashed by 111.24% to -$10.4 million in 2022, then surged by 4967.31% to $506.2 million in 2023, then soared by 90.95% to $966.6 million in 2024, then dropped by 22.61% to $748.1 million in 2025.
  • Per Business Quant, the three most recent readings for LLY's Deferred Taxes are $748.1 million (Q4 2025), -$501.4 million (Q3 2025), and $1.1 billion (Q2 2025).